Vogt-Koyanagi-Harada (VKH) syndrome is an inflammatory condition characterized by bilateral uveitis, vitiligo, poliosis, alopecia, and dysacousia. The syndrome results from a T cell mediated autoimmune attack on melanocytes in genetically susceptible individuals. We present a case of VKH syndrome and propose that the alopecia and poliosis described in the original reports by ophthalmologists could instead be alopecia areata with re-growth of white hair.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment.
J Dermatol
January 2025
Pfizer, Groton, Connecticut, USA.
Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments.
View Article and Find Full Text PDFPopulation exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata.
CPT Pharmacometrics Syst Pharmacol
January 2025
Pfizer Inc., Paris, France.
Ritlecitinib is an orally bioavailable, small molecule that has been approved by the U.S. Food and Drug Administration (FDA) as a once-daily oral treatment option for people 12 years of age and older with severe alopecia areata.
View Article and Find Full Text PDFBaricitinib for the Treatment of Moderate-to-Severe Alopecia Areata.
Balkan Med J
January 2025
Department of Dermatology, Bezmialem University Faculty of Medicine, İstanbul, Türkiye.
Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods.
BMC Med Inform Decis Mak
January 2025
Department of Pharmacy, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Background: Alopecia areata (AA) is a common non-scarring hair loss disorder associated with autoimmune conditions. However, the pathobiology of AA is not well understood, and there is no targeted therapy available for AA. METHODS: In this study, differential gene expression analysis, immune status assessment, weighted correlation network analysis (WGCNA), and functional enrichment analysis were performed to identify shared genes associated with both immunological response and AA.
View Article and Find Full Text PDFPathogenesis of paradoxical alopecia areata during dupilumab therapy: What is known and unknown.
Int J Dermatol
January 2025
Department of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!